Programme

Programme
6-7 November 2015
Langham Hotel, Auckland
Friday
6 November
8.30 8.40 Mihi Whakatau
Room: The Great Room
Opening by the Minister of Health, the Honourable Jonathan Coleman
Introduction of Minister by Dr Lee Mathias, Chairman,
Health Promotion Agency
Session 1: 8.55 9.05
9.10
9.20
9.30
Welcome and Melanoma Summit Overview: Dr Chris Boberg
Challenge to Participants from a Patient Perspective:
Kathryn Williams
Room: The Great Room
Chair: Dr Chris Boberg
Trends in Melanoma Incidence and Mortality in New Zealand:
Dr Mary Jane Sneyd
Standards of Service Provision for Melanoma Patients in
New Zealand: Mr Richard Martin
Melanoma Early Detection and Diagnosis: Associate Professor
Cliff Rosendahl and Associate Professor Amanda Oakley
10.15 Morning Tea
Great Room IV
Session 2: 10.45 Surgical Management of Melanoma: Professor Charles Balch
12.15 Questions and Discussion
11.30 Oncological Management of Melanoma: Professor Antoni Ribas
12.30 Lunch
Room: The Great Room
Chair: Mr Richard Martin
Great Room IV
Session 3: 1.30 Improving Services and Outcomes for Patients in New Zealand.
A Patient-Centred Focus on Coordination of Care: Natalie James,
Mr John Kenealy, Dr Andrew MacGill, Mr Jeremy Simcock,
Kathryn Williams, Dr Richard Sullivan (Chair)
Room: The Great Room
(1A) Challenging Cases: Exploring Management Options
Room: Crystal Room 1
(1B) Chaos and Clues in Action
Room: Gallery 4
(1C) Primary Prevention
Room: Gallery 1
(1D) Pathology of Difficult Melanocytic Tumours and Spitz Variants
Room: Crystal Room 2
Chair: Trish Leathem
2.15 Concurrent Breakout Sessions 1
2
Chair: Dr Catherine Barrow
Co-Chairs: Dr Chris Boberg and
Dr Mark Foley
Chair: Kath Blair
Co-Chairs: Dr Patrick Emanuel
and Dr Ben Tallon
3.15am Afternoon Tea
3.45
Concurrent Breakout Sessions 2
(2A) Challenging Cases: Exploring Management Options
Great Room IV
Room: Crystal Room 1
Chair: Dr Ben Tallon
(2B) Chaos and Clues in Action
Room: Gallery 4
(2C) Snapshots of Innovative Initiatives in Primary Prevention
Room: Crystal Room 2
(2D) The Impact of Diagnosis and a Tool for Assessing Patient Distress
Room: Gallery 1
4.45 MelNet AGM
The Great Room
5.15 Poster Presentation Session and Cash Bar
Great Room IV
7.00 Conference Dinner
Room: Great Room
Co-Chairs: Dr Chris Boberg and
Dr Mark Foley
Chair: Kath Blair
Chair: Trish Leathem
Guest Speaker: Sir Brian Lochore
Saturday
7 November
7.15am
Breakfast Panel: The Future of Melanoma Treatment in
New Zealand
Overview of Rapid Changes to the Landscape of Melanoma Treatment, the
Availability of New Treatments in New Zealand and Implications for Funding:
Professor Antoni Ribas, Professor Rod Dunbar, Dr Rosalie Fisher,
Dr George Laking, Dr Andrew Simpson
Room: The Great Room
8.50 Room: The Great Room
Chair: Dr Catherine Barrow
Session 1
9.30 10.00 Our Changing Understanding of Melanoma Aetiology and Its
Implications for Prevention and Control: Professor David Whiteman
Chair: Mr Jeremy Simcock
Action to Address Melanoma Risk: Panel Presentations and Discussion
Associate Professor Anthony Reeder, Dr Mary Jane Sneyd, Professor
David Whiteman
Innovations and Models of Best Practice (See page seven for topics)
Stream One: Clinical Management
Room: The Great Room,
Chair: Mr Jeremy Simcock
Stream Two: Diagnosis and Management
Room: Crystal Room 1
Chair: Dr Chris Boberg
3
11.00 Morning Tea
Great Room IV
11.30 Concurrent Workshops
(1) Are Primary Prevention Campaigns Worth the Effort?
Room: Gallery 1
(2) Dermatoscopy/Histopathology Correlation: The Challenge of Diagnosing Melanoma
Room: Crystal Room 1
(3) National Approach to Melanoma Translational Research in NZ
Room: Gallery 4
(4) Lymphoedema and Other Treatment Complications
Room: Gallery 2
(5) Sentinel Node Biopsy: A Review of the Evidence
Room: Crystal Room 2
1.00 Lunch
Chair: Claire Austin
Co-Chairs: Dr Patrick Emanuel and
Dr Ben Tallon
Co-Chairs: Dr Catherine Barrow and
Professor Mike Eccles
Chair: Trish Leathem
Chair: Mr Richard Martin
Great Room IV
Session 2: 2.00 Workshop Reports and Proposed Resolutions
3.20 Closing Remarks
2.30
3.30 The Future of Melanoma Prevention, Diagnosis, Treatment, Care
and Research: Professor David Whiteman, Associate Professor Cliff
Rosendahl, Professor Charles Balch and Professor Antoni Ribas
Close and Afternoon Tea
Trade display locations:
1. Roche
2. Melanoma New Zealand
3. Cancer Society of New Zealand
4. Australia/New Zealand
Melanoma Trials Group
5. MoleMap
6. Abacus ALS
7. Leo Pharma
8. Esteem/Dermite
4
Chair: Mr Gary Duncan
Great Room IV
Breakout Session and
Workshop Locations
9. MSD
Room: The Great Room
The Great
Room IV
Friday
6 November
Breakout Sessions and Workshops
2.15 - 3.15pm
(1A) Challenging Cases: Exploring Management Options
This session will focus on clinical management of challenging or unusual cases
of melanoma.A multidisciplinary panel, including Professor Antoni Ribas, will
discuss cases presented. It will be repeated in Breakout Session 2A. Delegates
are encouraged to attend only one of these sessions.
Room: Crystal Room 1
This session led by Associate Professor Cliff Rosendahl will teach the basics of
the ‘chaos and clues’ approach to dermatoscopy in diagnosing melanoma and
will demonstrate its practical application to specific cases. It will be repeated
in Breakout Session 2B. Delegates are encouraged to attend only one of these
sessions.
Room: Gallery 4
This session will begin with approaches being trialled to support effective
communication of evidence-based advice on primary prevention in primary
care. Also to be presented are results of the most recent Consumer NZ Mystery
Shopper Sunbed Survey. Recent survey findings on sun protection practices in
NZ secondary schools and what is needed for a national SunSmart secondary
school programme also will be addressed.
Room: Gallery 1
This session will explore a range of cases, including ALK fusion Spitz,
cannonball melanoma, multinucleation/senescence in malignant melanoma,
BAPoma and dedifferentiated melanoma. The role of new and emerging
diagnostic molecular testing also will be discussed.
Room: Crystal Room 2
Chair: Dr Catherine Barrow
(1B) Chaos and Clues in Action
Co-Chairs: Dr Chris Boberg
and Mark Foley
(1C) Primary Prevention
Chair: Kath Blair
Presenters: Bhama Rajiv,
Belinda Castles,
Professor Tony Reeder
(1D) Pathology of Difficult Melanocytic Tumours and
Spitz Variants
Co-Chairs: Dr Patrick Emanuel
and Dr Ben Tallon
Presenters: Dr Patrick Emanuel,
Dr Ben Tallon, Dr Daniel Ng
3.45 - 4.45pm
(2A) Challenging Cases: Exploring Management Options
This session will focus on clinical management of challenging or unusual cases
of melanoma. A multidisciplinary panel, including Professor Charles Balch, Dr
Rosalie Fisher and Dr Stephen Ng, will discuss cases presented. This will be a
repeat of Breakout Session 1A. Delegates are encouraged to attend only one of
these sessions.
Room: Crystal Room 1
Chair: Dr Ben Tallon
5
(2B) Chaos and Clues in Action
This session led by Associate Professor Cliff Rosendahl will teach the basics
of the ‘chaos and clues’ approach to dermatoscopy in diagnosing melanoma
and will demonstrate its practical application to specific cases. It will be a
repeat of Breakout Session 1B. Delegates are encouraged to attend only one
of these sessions.
Room: Gallery 4
1.
What Shade? Inter-sector Collaboration to Improve Community Health
and Wellbeing: Kerry Hocquard
Room: Crystal Room 2
3.
Start Being Aware of the Skin You’re In: Dr Louise Reiche
Co-Chairs: Dr Chris Boberg and
Dr Mark Foley
(2C) Snapshots of Innovative Initiatives in Primary Prevention
2.
4.
5.
Chair: Kath Blair
UV2Day: An App for Daily UV Index Forecasts: Dr Ben Liley
Sun Protection at Secondary School Athletic Events: Dr Bronwen McNoe
Translating Genomics to Improve Skin Cancer Prevention: Motivating
Preventive Behaviours Using Knowledge of Personal Genomic Risk:
Dr Anne Cust
(2D) The Impact of Diagnosis and a Tool for Assessing
Patient Distress
Led by Cancer Society Auckland health psychologists Alexandra Leggat and
Sarah McCambridge, this session will identify some of the most common
psychosocial issues for patients and their families and whānau. Recent
service-based research will be reported and a ‘thermometer’ for assessing
distress will be demonstrated.
5.15 – 6.00 pm
Room: Gallery 1
Chair: Trish Leathem
Great Hall 4
Poster Presentation Session
1.
How Well Do NZ Sunscreens Comply with the ANZ Melanoma Practice
Guidelines and Regional Labelling Standards?
Dr Jon Mathy
3.
The Comparison of Chemotherapeutic Regimens for the Treatment of
Metastatic Uveal Melanoma
Dr Valeriya Nazarova
The Epidemiology of Non-melanoma Skin Cancers in Auckland,
New Zealand
Dr Ashwini Pondicherry
Multiple Primary Melanomas
Dr Ken Ip
A Retrospective Analysis of 55 Patients Diagnosed with 57 Blue Naevi
through the Waikato Virtual Lesion Clinic
Dr Jenny Chung
P53 Codon 248 Gene Polymorphism as a Possible Marker in Melanoma
Risk and Metastasis
Dr Svetlana Rubakovic
2.
4.
5.
6.
7.
8.
9.
10.
11.
6
12.
Introduction of Real-time UV Radiation Public Warning Display
Dr Franz Strydom
Diffuse Melanosis Cutis in BRAF Mutation Positive Metastatic
Melanoma: A Case Report and Literature Review
Dr Paula Barlow
Curiosity and Innovation in Skin Cancer Surgery
Dr Sharad Paul
The Management of Primary Cutaneous Melanoma in a Provincial
Setting: A Review of Current Practice
Dr Will Anderson
Patient Information for Patients with Melanoma: Understanding
Sentinel Node Biopsy
Tracey King
Working to Prevent Avoidable Deaths from Melanoma and
Support Research
Linda Flay
Saturday 7
November
10.00-11am
Sessions on Innovations and Models
of Best Practice
Stream 1: Clinical Management
Room: The Great Room
1.
Interdisciplinary Comparison of Skin Cancer Treatment in the
Bay of Plenty
Dr Franz Strydom
3.
Management of Melanoma after Shave Biopsy
Dr Jon Mathy
Excision Margins and Sentinel Lymph Node Status as Prognostic Factors
in Thick Melanoma of the Head and Neck: A Retrospective Study
Dr Olivia Ruskin
Adjuvant Radiotherapy (ART) Following Lymphadenectomy for Stage III
Melanoma - Where to from Now?
Dr Bryan Burmeister
2.
4.
5.
6.
7.
8.
Chair: Mr Jeremy Simcock
A Tale of Melanoma in Canterbury: The Patient Experience
Dr James Eason
Assessment of Tumour Mitotic Rate in Primary Cutaneous Malignant
Melanomas ≤1mm in Thickness
Dr Ben Tallon
Lymphadenectomy for Stage III Melanoma: A Ten Year Review
Dr Rahul Jayakar
One Hundred Years of ANZAC - Together Let’s Fight a New Common
Foe -Melanoma!
Elizabeth Paton
Stream 2: Diagnosis and Management
Room: Crystal Room 1
1.
A Teledermatoscopic Based Virtual Lesion Clinic (VLC) to Optimise
Melanoma Referrals to a Public Hospital in Auckland
Dr Amber Congalton
3.
Towards Unified Referral Criteria for High Suspicion of Cancer:
Characteristics of Truncal Melanomas Diagnosed at the Waikato Virtual
Lesion Clinic
Dr Lydia Chan
Outcomes Following MoleMap Examinations and Recommendations for
Biopsy in Waikato in 2010-12
Professor Mark Elwood
MoleMap Tele-dermatology Auditing System
Dr Martin Haskett
2.
4.
5.
6.
7.
8.
Chair: Dr Chris Boberg
HSCAN Criteria Applied to Benign Lesions Referred to Waikato Virtual
Lesion Clinic (WVLC)
Dr Nicola Salmon
Melanoma Risk Factors in Patients Attending Waikato Virtual
Lesion Clinic
Dr Georgina Harvey
Analysis of 200,000 Patient Visits to MoleMap
Dr Katy Doherty
Unpredictability of Lentigo Maligna - Personal Experiences
Mr Geoff Barnett
7
11.30am - 1.00pm
Workshops
(1) Are Primary Prevention Campaigns Worth the Effort?
This workshop will explore the evidence base for primary prevention and
will include presentations on recent public health solaria surveys and the
Health (Protection) Amendment bill. A multi-disciplinary panel will address
requirements for effective interventions and, along with participants, will
identify priorities for action to reduce the incidence of melanoma and nonmelanoma skin cancers in New Zealand.
Room: Gallery 1
This interactive workshop will feature a panel of clinicians who will discuss
with participants specific cases that demonstrate the challenges and benefits
of correlating dermatoscopy and histopathology in the diagnosis of melanoma.
Room: Crystal Room 1
Chair: Claire Austin
Presenters: Professor David Whiteman,
Associate Professor Tony Reeder,
Louise Sandford, Martin Gledhill
(2) Dermatoscopy/Histopathology Correlation:
The Challenge of Diagnosing Melanoma
Co-chairs: Dr Patrick Emanuel and
Dr Ben Tallon
Presenters: Associate Professor
Cliff Rosendahl, Associate Professor
Amanda Oakley, Dr Ben Tallon
(3) National Approach to Melanoma Translational Research
in New Zealand
This workshop involving clinicians and researchers will present and discuss
a recent stocktake of melanoma research in New Zealand and will enable
researchers to briefly describe current projects or programmes, with a view to
identifying opportunities for collaboration.
Room: Gallery 4
Co-Chairs: Professor Mike Eccles and
Dr Catherine Barrow
Presenters: Professor Mike Eccles
and contributors to MelNet
Research Stocktake
(4) Lymphoedema and Other Treatment Complications
With reference to case studies, this workshop led by Clinical Nurse
Coordinator Peggy Williams of the Lymphoedema Service at Counties
Manukau Health will present the basic knowledge and skills needed to assess,
reduce the risk of and manage surgery-related lymphoedema and other
treatment complications, including seromas.
Room: Gallery 2
This interactive workshop will feature a panel of clinicians, surgeons and
dermatologists, who will discuss changes in thinking about the role of sentinel
node biopsy and other treatment issues.
Room: Crystal Room 2
Chair: Trish Leathem
(5) Sentinel Node Biopsy: Review of the Evidence
8
Chair: Mr Richard Martin
Panellists: Professor Charles Balch,
Dr Patrick Emanuel, Mr John Kenealy,
Dr Fergus Oliver, Mr James Shaw
International
Guest Speakers
Professor Charles Balch
Charles M. Balch, MD, FACS, PhD, is Professor of Surgery at the University of
Texas Southwestern Medical Center in Dallas. For the past 39 years Professor
Balch has led a distinguished career as a clinical and academic surgical
oncologist and is regarded as one of the leading melanoma experts in the
world. He is the editor of Cutaneous Melanoma, the authoritative textbook on
melanoma, and his contributions to the melanoma literature (which includes
over 147 published articles, 6 books, and 154 book chapters) relate to his
clinical investigations involving the natural history of melanoma, prognostic
factors predicting clinical outcome and standards of surgical treatment.
Professor Balch also is the founding Editor-in-Chief of the Annals of Surgical
Oncology and the Editor-in-Chief for Patient Resource Cancer Guides, which
distribute over one million cancer guides (with 14 different titles) to cancer
patients each year.
Professor Balch has published extensively on the conduct and methodology
of clinical research. He and his colleagues performed one of the first prognostic factors analysis for melanoma in a
landmark paper, which was the first to use the Cox multifactorial regression analysis. They were the first to identify
the major prognostic factors for Stage I, II and III melanoma that were the independent predictor of survival, including
melanoma ulceration as a key predictor of metastases and interferon sensitivity. Their research on the natural history
and predictive factors of melanoma clinical outcome essentially redefined the criteria now used worldwide for
stratification and end results reporting of clinical trials as well as TNM staging for melanoma.
Professor Antoni Ribas
Antoni Ribas, MD, PhD is Professor of Medicine, Professor of Surgery and Professor of
Molecular and Medical Pharmacology at the University of California Los Angeles
(UCLA). He is the Director of the Tumor Immunology Program at the Jonsson
Comprehensive Cancer Center, Vice-President of the Society for Melanoma Research, a
member of the American Society of Clinical Investigation and the Chair of the Melanoma
Committee at SWOG (a cancer research cooperative group that designs and conducts
multidisciplinary clinical trials). As both a physician and a scientist, Professor Ribas is a
recognised expert and key opinion leader in the treatment of patients with advanced
melanoma and tumour immunotherapy and has published over 200 manuscripts and
book chapters in this field. He also has received numerous awards for his work.
Professor Ribas trained at the University of Barcelona, with postdoctoral research and
clinical fellowships at UCLA. His laboratory and clinical research in melanoma focuses
on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, antiPD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. His NIH,
State of California and private foundation-supported research laboratory develops models of disease to test new
therapeutic options and studies mechanism of action of treatments in patients. Professor Ribas is a permanent
committee member of the National Cancer Institute (NCI) grant review panels and an elected member of the
American Society of Clinical Investigation (ASCI). He also serves as a consultant for numerous clinical development
drug programmes for major companies.
9
Associate Professor Cliff Rosendahl
Cliff Rosendahl, MB, BS, PhD, is Associate Professor at The University of Queensland
where he is director of the Master of Medicine (Skin Cancer) degree course. He is a
General Practitioner of 38 years’ experience, including rural general practice and
work in the field of forensic medicine, and he has worked in a Brisbane suburban
practice as a general practitioner with a special interest in skin cancer, particularly
melanoma. Professor Rosendahl also has collaborated with colleagues in Brisbane
and Austria to research the early diagnosis of melanoma, and together they have
evaluated and promoted the diagnostic methods ‘Chaos and Clues and Prediction
without Pigment’. His other field of research is with respect to an analysis of the
Skin Cancer Audit Research Database (SCARD), for which he is founder and director,
to assess the impact of sub-specialisation in the field of skin cancer and the use of
dermatoscopy on diagnostic accuracy with respect to melanoma.
Professor Rosendahl has published over 40 papers in peer-review scientific journals
and is co-author of the textbook Dermatoscopy, which has been published in English, Polish and Russian, and he is a
contributing author to several other textbooks in English and one in Spanish. From 2010-2012 he was Vice President of
the Skin Cancer College of Australia and New Zealand. Professor Rosendahl has a busy schedule as an invited speaker to
general practitioner and dermatologist groups both in Australia and internationally.
Professor David Whiteman
David Whiteman, B Med Sc, MBBS (Hons), PhD, FAFPHM, is Head of the Cancer
Control Laboratory, Coordinator of the Population Health Department and
Coordinator of the Melanoma and Skin Cancer Research Centre at the QIMR
Berghofer Medical Research Institute in Brisbane, Australia. Professor Whiteman,
a medical epidemiologist with a special interest in the causes, control and
prevention of cancer, received his medical degree from the University of
Queensland in 1991. Following a PhD in cancer epidemiology and specialist
training in public health medicine, he was invited to the University of Oxford as a
Nuffield Medical Research Fellow to work in several areas of cancer research.
Having returned to Brisbane in 2000, he now leads a large programme of cancer
research comprising national and international studies of melanoma and other
cancers.
Professor Whiteman has an international reputation for research into melanoma and skin cancer, and particularly the
public health aspects of cancer control. To that end, he has pursued two parallel but complementary paths, focusing
on discovering how environmental and genetic factors interact to cause cancer on the one hand, and then applying
this knowledge to the prevention and control of disease on the other. In addition to his research activities, he is a
member of the Academy of the National Health and Medical Research Council of Australia (NHMRC) and Chair of the
Barrett’s Neoplasia Guidelines Committee for the Cancer Council Australia. In 2006, he was awarded a Fulbright Senior
Scholarship to visit cancer researchers in the United States.
10
Continuing Medical Education
The Melanoma Summit 2015 has been endorsed by The Royal New Zealand
College of General Practitioners (RNZCGP) and has been approved for up to
13.00 credits CME for the General Practice Educational Programme (GPEP)
Years 2 and 3 and Maintenance of Professional Standards (MOPS) purposes. The Melanoma Summit 2015 has been approved in the Royal Australasian
College of Surgeons (RACS) CPD Program. Fellows who participate in the twoday Summit can claim 13 points in Maintenance of Knowledge and Skills. RACS
members who wish to receive credit must provide their RACS member ID
(a six-digit number also known as the Fellowship ID) to the MelNet
Coordinator ([email protected]) no later than Monday 16 November.
Acknowledgements
The MelNet Executive Committee and the Health Promotion Agency, as hosts of
the Melanoma Summit 2015, would like to thank all of the speakers, especially
the international guests, as well as the chairs and panellists of the breakout
sessions and workshops. All have been very generous in donating their time
and expertise.
The MelNet Executive Committee and Health Promotion Agency also would
like to thank its sponsorship partners whose support has made the Melanoma
Summit 2015 possible.
The MelNet Executive Committee acknowledges and thanks the Health
Promotion Agency and its staff, who gave freely of their time and energy to
plan the Melanoma Summit 2015. Without the Health Promotion Agency’s
ongoing support, MelNet as an organisation and its ability to co-host biennial
summits would not be possible.
MelNet Executive Committee
Mr Gary Duncan, Plastic Surgeon, Chair
Dr Chris Boberg, General Practitioner, Deputy Chair
Dr Catherine Barrow, Consultant Medical Oncologist
Kath Blair, Health Promotion Agency
Professor Mike Eccles, Biomedical Researcher
Dr Patrick Emanuel, Histopathologist
Trish Leathem, Skin Cancer Clinical Nurse Specialist
Mr Richard Martin, Cutaneous Surgical Oncologist
Mr Jeremy Simcock, Plastic Surgeon
Dr Ben Tallon, Consultant Dermatologist and Dermatopathologist
11
Melanoma
Summit 2015
Partners
Platinum Partners
Silver Partners
Bronze Partners
Hosts